![]() |
Lung Cancer |
Free Subscription
1 AJR Am J Roentgenol |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Lung Cancer is free of charge.
Pericardial Fat and Primary Tumor Radiomics for Predicting Occult N2 Disease and
Survival in Clinical Stage I Non-Small Cell Lung Cancer: Multicenter Study With
Biologic Correlation.
AJR Am J Roentgenol. 2025 May 21. doi: 10.2214/AJR.25.32861.
PubMed
Abstract available
Genomic landscape of clinically acquired resistance alterations in patients
treated with KRAS(G12C) inhibitors.
Ann Oncol. 2025;36:682-692.
PubMed
Abstract available
ASO Author Reflections: Controversies at the Tumor Board-The Gray Areas in the
Multimodality Treatment of Resectable Non-small Cell Lung Cancer.
Ann Surg Oncol. 2025 May 19. doi: 10.1245/s10434-025-17459.
PubMed
Longitudinal Trajectory of Patient-Reported Fatigue in Patients Undergoing
Thoracoscopic Lung Cancer Surgery.
Ann Surg Oncol. 2025 May 17. doi: 10.1245/s10434-025-17444.
PubMed
Abstract available
Safety and Feasibility of Novel Single-Port Robotic-Assisted
Lobectomy/Segmentectomy for Lung Cancer.
Ann Thorac Surg. 2025 May 15:S0003-4975(25)00420.
PubMed
Abstract available
Clinical and Genetic Characteristics of Early-Onset Lung Adenocarcinoma in a
Large Chinese Cohort.
Ann Thorac Surg. 2025;119:1196-1204.
PubMed
Abstract available
EGFR exon 20 insertions mutation in lung adenocarcinoma and its response by
high-dose of Furmonertinib: a real-world study.
BMC Cancer. 2025;25:900.
PubMed
Abstract available
Impact of doctor-shopping behavior on patient survival in lung cancer: findings
from a 11-year cohort study using Korean claims data.
BMC Cancer. 2025;25:914.
PubMed
Abstract available
Disparities in receipt of palliative-intent treatment among disaggregated
Hispanic populations with breast, lung, and prostate cancer in the United States.
Cancer. 2025;131:e35903.
PubMed
Abstract available
Phase I/II Study of Tifcemalimab, an Anti-B and T-lymphocyte Attenuator Antibody,
in Combination with Toripalimab in Previously Treated Advanced Lung Cancer.
Clin Cancer Res. 2025 May 16. doi: 10.1158/1078-0432.CCR-25-0022.
PubMed
Abstract available
PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged
NSCLC and Central Nervous System Disease.
Clin Lung Cancer. 2025;26:263-266.
PubMed
Abstract available
Multiple Sclerosis and Lung Cancer: A Single Cancer Center Experience in
Philadelphia.
Clin Lung Cancer. 2025 Apr 28:S1525-7304(25)00086.
PubMed
Abstract available
Distinct Role of TP53 Co-mutations in Different EGFR Subtypes Mediating the
Response to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
Clin Lung Cancer. 2025 Apr 23:S1525-7304(25)00078.
PubMed
Abstract available
Real-World Creatinine-Based Estimates of Acute and Chronic Kidney Dysfunction in
Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Receiving
Tyrosine Kinase Inhibitors.
Clin Lung Cancer. 2025 Apr 8:S1525-7304(25)00059.
PubMed
Abstract available
Longitudinal Analysis of Recurrence and Risk Factors of Early-Stage Resected
Adenocarcinoma With Common EGFR Mutations: A Multicenter Retrospective Cohort
Study in South Korea.
Clin Lung Cancer. 2025;26:314-323.
PubMed
Abstract available
First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing >/= 50%
PD-L1 (ESCKEYP GFPC 05-2018).
Clin Lung Cancer. 2025;26:331-337.
PubMed
Abstract available
Racial Diversity and Co-Mutational Analysis of Biologically Relevant Alterations
in EGFR Mutant Lung Cancers.
Clin Lung Cancer. 2025;26:307-313.
PubMed
Abstract available
Perioperative and long-term survival outcomes following resection of stage iv
non-small-cell lung cancer: a multi-center experience.
Eur J Cardiothorac Surg. 2025 May 20:ezaf156. doi: 10.1093.
PubMed
Abstract available
Decoding the complexity: mechanistic insights into comorbidities in idiopathic
pulmonary fibrosis.
Eur Respir J. 2025;65:2402418.
PubMed
Abstract available
Randomized Evaluation of the PET-Adjusted IMRT for NSCLC Trial (REPAINT).
Int J Radiat Oncol Biol Phys. 2025;122:365-373.
PubMed
Abstract available
Concurrent and Consolidative Carboplatin Plus Nab-Paclitaxel or Paclitaxel in
Locally Advanced NSCLC: A Multicenter, Randomized Clinical Trial.
Int J Radiat Oncol Biol Phys. 2025;122:374-382.
PubMed
Abstract available
Intracranial disease control and survival among patients with KRAS-mutant lung
adenocarcinoma and brain metastases treated with SRS.
Int J Radiat Oncol Biol Phys. 2025 Feb 8:S0360-3016(25)00093.
PubMed
Abstract available
Risk-Based Lung Cancer Screening in Clinical Practice.
J Thorac Oncol. 2025 May 14:S1556-0864(25)00717.
PubMed
Abstract available
Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and
MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.
J Thorac Oncol. 2025 May 16:S1556-0864(25)00720.
PubMed
Abstract available
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable
and Unresectable Stage III Non-Small Cell Lung Cancer.
JAMA Oncol. 2025 May 22. doi: 10.1001/jamaoncol.2025.1115.
PubMed
Abstract available
Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and
matched treatment of central nervous system metastases.
Nat Med. 2025;31:1547-1556.
PubMed
Abstract available
Epigenetic assessments of alcohol consumption predict mortality in smokers at
risk for lung cancer in the prostate, lung, colorectal and ovarian cancer
screening trial.
PLoS One. 2025;20:e0322783.
PubMed
Abstract available
Phase separation of RXRgamma drives tumor chemoresistance and represents a
therapeutic target for small-cell lung cancer.
Proc Natl Acad Sci U S A. 2025;122:e2421199122.
PubMed
Abstract available
Thank you for your interest in scientific medicine.